Hercules Capital
Hercules Capital is a capital market company that lends to technology, life sciences, and sustainable technology companies.
Business Model:
Revenue: $294M
Employees: 51-200
Rankings
Detailed Hercules Capital Information
Geographic Data
Address: 400 Hamilton Avenue
City: Palo Alto
State: CA
Zip: 94301
Country: US
Financial Info
Stage:
Raised Last:
$7M
Raised Total:$7M
Social
Twitter
Linkedin
Crunchbase
Metrics
3,157,853Website Global Rank
5,147Website Monthly Traffic
Twitter Followers
Description
Hercules is the largest non-bank lender to venture capital-backed companies at all stages of development in a broadly diversified variety of technology, life sciences, and sustainable and renewable technology industries. With over a decade of experience in venture debt, Hercules is uniquely positioned to quickly create innovative financing solutions that perfectly fit within a company&s;s existing capital structure and map to its business objectives. Recognized as the industry leader, Hercules understands the flexibility these types of companies need and has the experience to work closely with them, even through challenging times, to help them reach critical milestones. Hercules&s; deep sector expertise, geographic presence and its strong capital base have made Hercules the lender of choice for more than 480 innovative companies.
Contact Phone:
+16502893060
Contact Email:
Hercules Capital went public on 5/4/2012 on the NYSE
Listed Exchange:
NYSE
IPO Date:
5/4/2012
Ticker Symbol:
HTGC
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2007 | Everyday Health Group | Debt Financing | 8M |
| 11/2007 | Zayo | Debt Financing | 85M |
| 9/2021 | Corium International | Debt Financing | 235M |
| 6/2017 | Concert Pharmaceuticals | Post-IPO Debt | 30M |
| 9/2021 | 3Gtms | Private Equity Round | 0 |
| 7/2018 | Acacia Pharma | Debt Financing | 30M |
| 10/2008 | Blurb | Debt Financing | 2.5M |
| 7/2018 | Merrimack Pharmaceuticals | Post-IPO Debt | 25M |
| 7/2007 | Purcell Systems | Venture Round | 15M |
| 11/2014 | nContact Surgical | Debt Financing | 20M |
| 2/2019 | Urovant Sciences | Debt Financing | 100M |
| 2/2015 | SparkPost | Debt Financing | 8M |
| 2/2010 | Propel Fuels | Debt Financing | 8M |
| 1/2015 | MELA Sciences | Post-IPO Debt | 10M |
| 7/2016 | Aprecia Pharmaceuticals | Debt Financing | 30M |
| 4/2016 | FuelCell Energy | Post-IPO Debt | 25M |
| 12/2014 | SOASTA | Debt Financing | 15M |
| 7/2014 | UniQure | Post-IPO Debt | 20M |
| 12/2007 | Shocking Technologies | Debt Financing | 4M |
| 11/2013 | Celsion | Post-IPO Debt | 20M |
| 3/2016 | Mast Therapeutics | Post-IPO Debt | 15M |
| 3/2010 | Velocity Technology Solutions | Debt Financing | 25M |
| 11/2012 | TransMedics | Venture Round | 36M |
| 10/2022 | Bright Machines | Debt Financing | 0 |
| 3/2017 | 908 Devices | Debt Financing | - |
| 8/2020 | AVEO Oncology | Post-IPO Debt | 35M |
| 12/2018 | Contentful | Series D | 33.5M |
| 4/2007 | IKANO Communications | Post-IPO Debt | 22.5M |
| 8/2022 | Provention Bio | Post-IPO Debt | 125M |
| 7/2013 | BioAmber | Post-IPO Debt | 25M |
| 8/2007 | Quartics | Venture Round | 7.5M |
| 9/2014 | ChromaDex | Post-IPO Debt | 5M |
| 1/2011 | Anthera Pharmaceuticals | Post-IPO Debt | - |
| 10/2013 | Cleveland BioLabs | Post-IPO Debt | 10M |
| 2/2014 | ADMA Biologics | Post-IPO Debt | 15M |
| 1/2008 | Kadoink | Debt Financing | 2.5M |
| 1/2006 | Optovia Corporation | Debt Financing | 5M |
| 10/2006 | IWatt | Venture Round | 7M |
| 4/2018 | Dashlane | Debt Financing | 10M |
| 4/2019 | Dashlane | Debt Financing | 30M |
| 1/2012 | Clustrix | Debt Financing | 4M |
| 6/2015 | Proterra | Series D | 55M |
| 11/2007 | WildTangent | Debt Financing | 20M |
| 5/2015 | ReachLocal | Post-IPO Debt | 25M |
| 8/2017 | BioQ Pharma | Debt Financing | - |
| 6/2010 | BuyerLink | Venture Round | 15M |
| 1/2006 | Simpler Networks | Debt Financing | 10M |
| 2/2017 | Sio Gene Therapies | Post-IPO Debt | 55M |
| 12/2005 | Atrenta | Venture Round | 10M |
| 9/2007 | Crux Biomedical | Venture Round | 250k |
| 1/2015 | Cerulean Pharma | Post-IPO Debt | 26M |
| 5/2007 | Neosil | Debt Financing | 10M |
| 7/2017 | Sebacia | Debt Financing | 16M |
| 1/2015 | Bellicum Pharmaceuticals | Post-IPO Debt | - |
| 11/2020 | Udacity | Debt Financing | 75M |
| 5/2006 | GameLogic | Debt Financing | 3M |
| 4/2014 | Alimera Sciences | Post-IPO Debt | 35M |
| 6/2012 | AMSC | Post-IPO Debt | 10M |
| 3/2005 | Omrix Biopharmaceuticals | Venture Round | 4.8M |
| 5/2014 | Medrobotics | Series E | 26M |
| 6/2013 | Anacor Pharmaceutical | Post-IPO Debt | 45M |
| 5/2015 | Machine Zone | Debt Financing | - |
| 6/2005 | Sportvision | Debt Financing | 4M |
| 5/2021 | SCYNEXIS | Post-IPO Debt | 60M |
| 11/2006 | Elixir Pharmaceuticals | Debt Financing | 15M |
| 2/2006 | HighRoads | Debt Financing | 2.5M |
| 8/2010 | Calera | Venture Round | 15M |
| 4/2007 | NuGEN Technologies | Debt Financing | 3M |
| 12/2013 | CTI BioPharma | Post-IPO Debt | 5M |
| 8/2021 | Novelion Therapeutics | Post-IPO Debt | 50M |
| 8/2006 | Agami System | Debt Financing | 11M |
| 9/2014 | Edge Therapeutics | Debt Financing | 10M |
| 3/2005 | Inxight Software | Debt Financing | 5M |
| 1/2007 | Blurb | Debt Financing | 2.5M |
| 2/2016 | CytRx | Post-IPO Debt | 40M |
| 12/2007 | hi5 | Debt Financing | 15M |
| 6/2014 | CareCloud Corporation | Debt Financing | 25.5M |
| 4/2007 | Rubicon Technology | Post-IPO Debt | 16M |
| 6/2016 | Plug Power | Post-IPO Debt | 70M |
| 12/2018 | Nabriva Therapeutics | Post-IPO Debt | 75M |
| 6/2022 | Akero Therapeutics | Post-IPO Debt | 0 |
| 4/2014 | JumpStart | Debt Financing | 13M |
| 3/2018 | Tricida | Debt Financing | 100M |
| 4/2022 | Viridian Therapeutics | Post-IPO Debt | 0 |
| 3/2013 | Medrobotics | Debt Financing | 10M |
| 12/2014 | MELA Sciences | Post-IPO Debt | 20M |
| 3/2017 | Verastem Oncology | Post-IPO Debt | 25M |
| 6/2022 | Geron | Post-IPO Debt | 0 |
| 4/2010 | PolyMedix | Post-IPO Equity | 14M |
| 4/2018 | RumbleON | Post-IPO Debt | 15M |
| 5/2021 | HiberCell | Debt Financing | 30M |
| 5/2009 | E-Band Communications | Series C | - |
| 3/2019 | Constellation Pharmaceuticals | Post-IPO Debt | 40M |
| 4/2007 | Tectura | Debt Financing | 22M |
| 3/2016 | Quanterix | Series D | 46M |
| 10/2005 | Affinity Express | Venture Round | 3M |
| 5/2010 | Chroma Therapeutics | Debt Financing | 15M |
| 12/2013 | Baxano Surgical | Post-IPO Debt | 15M |
| 3/2018 | Metalysis | Venture Round | 16.9M |
| 11/2020 | CloudBolt | Debt Financing | 20M |
| 12/2014 | ADMA Biologics | Post-IPO Debt | 5M |
| 6/2012 | just.me Inc | Debt Financing | 1.5M |
| 1/2020 | ChemoCentryx | Post-IPO Debt | 100M |
| 6/2017 | Antares Pharma | Post-IPO Debt | 35M |
| 10/2013 | InspireMD | Post-IPO Debt | 10M |
| 12/2020 | SingleStore | Series E | 0 |
| 7/2022 | Gritstone Bio | Post-IPO Debt | 80M |
| 6/2015 | Zosano Pharma | Post-IPO Debt | 15M |
| 5/2005 | WageWorks | Debt Financing | 20M |
| 2/2008 | Mode Media | Debt Financing | 20M |
| 7/2006 | BARRX Medical | Series C | 27.8M |
| 10/2005 | AGEIA Technologies | Series C | 27.5M |
| 2/2015 | SparkPost | Series C | 27M |
| 7/2015 | Gynesonics | Venture Round | 43M |
| 10/2011 | BrightSource Energy | Debt Financing | 35M |
| 5/2020 | SingleStore | Debt Financing | 50M |
| 9/2021 | Phathom Pharmaceuticals | Post-IPO Debt | 200M |
| 10/2022 | Tricida | Post-IPO Debt | 125M |
| 11/2022 | Kura Oncology | Post-IPO Debt | 125M |
| 6/2020 | G1 Therapeutics | Post-IPO Debt | 100M |
| 7/2006 | BabyUniverse, Inc. | Post-IPO Debt | 5M |
| 12/2013 | AcelRx Pharmaceuticals | Post-IPO Debt | 40M |
| 10/2017 | Myovant Sciences | Post-IPO Debt | 40M |
| 5/2010 | Alexza Pharmaceuticals | Post-IPO Debt | 15M |
| 8/2020 | UNITY Biotechnology | Post-IPO Debt | 80M |
| 1/2008 | Rise Broadband | Venture Round | 15M |
| 2/2020 | ZeroFOX | Series D | 74M |
| 7/2016 | Auris Medical | Post-IPO Debt | 12.5M |
| 2/2015 | Agile Therapeutics | Post-IPO Debt | 25M |
| 6/2005 | Merrimack Pharmaceuticals | Debt Financing | 9M |
| 7/2012 | Virident Systems | Venture Round | 5.7M |
| 3/2007 | Memory Pharmaceuticals | Post-IPO Debt | 10M |
| 10/2021 | Eloxx | Post-IPO Debt | 30M |
| 5/2010 | AVEO Oncology | Post-IPO Equity | 25M |
| 11/2012 | CapLinked | Series A | 0 |
| 12/2006 | Nexx Systems | Debt Financing | 10M |
| 8/2012 | Fortress Biotech | Post-IPO Debt | 15M |
| 1/2006 | Xillix | Debt Financing | 5.5M |
| 3/2012 | Alphabet Energy | Debt Financing | 2M |
| 12/2005 | Cradle Technologies | Series E | 0 |
| 8/2006 | NOVASYS MEDICAL | Debt Financing | 8M |
| 7/2007 | SiCortex | Debt Financing | 10M |
| 3/2009 | RazorGator | Debt Financing | 10M |
| 8/2005 | Adiana | Series D | 23M |
| 3/2019 | Aldeyra Therapeutics | Post-IPO Debt | 60M |
| 7/2007 | Prism Career Institute | Debt Financing | 3M |
| 5/2006 | OATSystems | Debt Financing | 6M |
| 3/2013 | NeuralStem | Post-IPO Debt | 8M |
| 1/2018 | Intuity Medical | Venture Round | 0 |
| 8/2022 | Alladapt Immunotherapeutics | Debt Financing | 50M |
| 6/2007 | Panacos Pharmaceuticals | Post-IPO Debt | 20M |
| 8/2015 | Modumetal | Venture Round | 33.5M |
| 3/2019 | FuelCell Energy | Post-IPO Debt | - |
| 3/2005 | RazorGator | Series A | 26M |
| 6/2014 | Nanotherapeutics | Debt Financing | 30M |
| 12/2012 | Comverge | Debt Financing | 34M |
| 2/2015 | Message Systems | Debt Financing | 27M |
| 4/2006 | Sirtris Pharmaceuticals | Debt Financing | - |
| 11/2006 | Elixir Pharmaceuticals | Series C | 0 |
| 5/2018 | CloudPay | Equity | 25M |
| 2/2016 | Aria Systems | Series E | 0 |
| 2/2022 | Lucira Health | Post-IPO Debt | 80M |
| 1/2013 | ADMA Biologics | Debt Financing | 6M |
| 7/2014 | SINTX Technologies | Post-IPO Debt | 0 |
| 11/2014 | Flowonix | Venture Round | 20M |
| 6/2016 | Flowonix | Debt Financing | 5M |
| 3/2007 | PSS Systems | Debt Financing | 5M |
| 4/2016 | ClearObject | Series E | 0 |
| 7/2022 | IVERIC bio | Post-IPO Debt | 250M |
| 3/2006 | Market Force Information | Debt Financing | 8M |
| 1/2019 | Mesoblast | Post-IPO Debt | 75M |
| 8/2022 | ATAI Life Sciences | Post-IPO Debt | 175M |
| 10/2007 | Diomed Holdings | Debt Financing | 10M |
| 12/2021 | Carwow | Debt Financing | 54.8M |
| 11/2012 | NuPathe | Post-IPO Debt | 8.5M |
| 1/2006 | Acceleron Pharma | Debt Financing | 8M |
| 1/2023 | AmplifyBio | Debt Financing | 50M |
| 8/2021 | Better Therapeutics | Debt Financing | 50M |
| 2/2015 | Melinta Therapeutics | Post-IPO Debt | 30M |
| 1/2018 | Gynesonics | Private Equity Round | 75M |
| 10/2014 | Gamma Medica | Series B | 0 |
| 3/2006 | RazorGator | Series B | 22.8M |
| 1/2015 | Aspire Bariatrics, Inc. | Debt Financing | 12M |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 12/2007 | E-Band Communications | Series B | 10M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 5/2012 | kaleo | Debt Financing | 15M |
| 6/2014 | Celator Pharmaceuticals | Debt Financing | 15M |
| 11/2022 | Phathom Pharmaceuticals | Post-IPO Debt | 40M |
| 5/2022 | Madrigal Pharmaceuticals | Post-IPO Debt | 250M |
| 1/2022 | TG Therapeutics | Post-IPO Debt | 70M |
| 2/2019 | TG Therapeutics | Post-IPO Debt | 60M |
| 2/2022 | Esme Learning Solutions | Venture Round | 15M |
| 11/2022 | Oak Street Health | Post-IPO Debt | 300M |
| 10/2021 | Locus Biosciences | Debt Financing | 25M |
| 12/2005 | Guava Technologies | Debt Financing | 10M |
| 10/2022 | Automation Anywhere | Debt Financing | 200M |
| 6/2005 | Sling Media | Debt Financing | 4M |
| 10/2006 | Atrenta | Venture Round | 0 |
| 12/2005 | Cornice | Series C | 97M |
| 4/2014 | Neos Therapeutics | Debt Financing | 20M |
| 6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 11/2022 | Locus | Series F | 0 |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 9/2016 | Druva | Series E | 51M |
| 12/2013 | ViewRay | Venture Round | 0 |
| 2/2023 | Skydio | Series E | 0 |
| 5/2007 | Intelliden | Series E | 10M |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 6/2015 | Proterra | Debt Financing | 25M |
| 3/2010 | InfoLogix | Venture Round | 3M |
| 6/2009 | Kamada | Venture Round | 20M |
| 8/2016 | Mattersight | Post-IPO Debt | 30M |
| 6/2013 | Rockwell Medical | Post-IPO Debt | 20M |
| 10/2020 | Bicycle Therapeutics | Debt Financing | 50M |
| 3/2006 | Compete, Inc. | Venture Round | 4M |
| 6/2005 | Labopharm | Debt Financing | 10M |
| 12/2014 | Dynavax Technologies | Debt Financing | 40M |
| 10/2022 | Replimune Group | Post-IPO Debt | 200M |
| 3/2021 | Humanigen | Post-IPO Debt | 80M |
| 5/2018 | Asensus Surgical | Post-IPO Debt | 40M |
| 7/2022 | IVERIC bio | Post-IPO Debt | 0 |
| 7/2022 | Gritstone Bio | Post-IPO Debt | 0 |
| 6/2022 | Geron | Post-IPO Debt | 0 |
| 6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2022 | Akero Therapeutics | Post-IPO Debt | 0 |
| 5/2022 | Madrigal Pharmaceuticals | Post-IPO Debt | 0 |
| 4/2022 | Viridian Therapeutics | Post-IPO Debt | 0 |
| 2/2022 | Esme Learning Solutions | Venture Round | 0 |
| 2/2022 | Lucira Health | Post-IPO Debt | 0 |
| 1/2022 | TG Therapeutics | Post-IPO Debt | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
